ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2809

Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed

Serge Ferrari1, E. Michael Lewiecki2, Peter W. Butler3, David L Kendler4, Nicola Napoli5, Shuang Huang3, Daria B Crittenden3, Nicola Pannacciulli3, E.S. Siris6 and Neil Binkley7, 1Geneva University Hospital, Geneva, Switzerland, 2New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 3Amgen Inc., Thousand Oaks, CA, 4University of British Columbia, Vancouver, BC, Canada, 5Campus Bio-Medico University of Rome, Rome, Italy, 6Columbia University Medical Center, New York, NY, 7University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Benefits, denosumab, fractures, osteoporosis and risk

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: 5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Osteoporosis is a chronic disease, yet skeletal safety events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ)—remain a concern with long-term treatment. Ten years of denosumab therapy in postmenopausal women with osteoporosis has demonstrated sustained and low vertebral and nonvertebral fracture rates, with low adverse event rates (Bone Lancet Diabetes Endocrinol 2017). Here, we generated a denosumab skeletal benefit/risk ratio derived from observed data and model-based estimates from the FREEDOM trial and its Extension.

Methods: Exposure-adjusted subject incidence per 100,000 subject-years of clinical, major osteoporotic, vertebral, nonvertebral, and hip fractures was calculated for long-term subjects randomized to denosumab in the 3-year FREEDOM trial and enrolled in the 7-year Extension (follow-up time on denosumab 3 to 10 years). Due to the lack of a long-term placebo group, fracture rates in a hypothetical cohort of 10-year placebo controls (virtual twins; Vittinghoff Stat Med 2010) were estimated: A regression model was generated using data from subjects randomized to PBO during FREEDOM and then enrolled in the Extension; a virtual twin with identical baseline characteristics to each long-term subject was derived; and fracture rates were then predicted for the untreated virtual twin group using the regression model. The number of fractures prevented per 100,000 subject-years was calculated as (virtual twin rate – long-term rate). AFF and ONJ incidences on denosumab were based on observed cases in the long-term group during the Extension; the virtual twin group was assumed to have no AFF or ONJ in the absence of treatment. A skeletal benefit/risk ratio was calculated from fractures prevented per AFF or ONJ observed.

Results: This analysis included 2343 subjects. The estimated number of clinical fractures prevented was 1403 per 100,000 subject-years (Table). There was 1 case of AFF and 7 ONJ (mild and moderate), corresponding to rates of 5 (AFF) and 35 (ONJ) per 100,000 subject-years. Hence, there were 281 and 40 clinical fractures prevented per AFF and ONJ observed, respectively. The skeletal benefit/risk ratio for other fracture endpoints is shown below (Table).

Conclusion: As long-term placebo-controlled fracture outcome studies in postmenopausal osteoporosis are not ethical, the virtual twin model provides a reasonable estimate of untreated fracture rates. Using this model, long-term denosumab therapy has a highly favorable benefit/risk profile when comparing fractures prevented per skeletal adverse event observed.

 


Disclosure: S. Ferrari, Amgen, UCB, AgNovos, 5,UCB, MSD, Amgen, 2; E. M. Lewiecki, Amgen, Radius, 2, 5,Radius, 8; P. W. Butler, Amgen Inc., 1, 3; D. L. Kendler, Eli Lilly, Amgen, AstraZeneca, 2,Eli Lilly, Amgen, Pfizer, 5,Eli Lilly, Amgen, 8; N. Napoli, Amgen, Lilly, 5; S. Huang, Amgen Inc., 1, 3; D. B. Crittenden, Amgen Inc., 1, 3; N. Pannacciulli, Amgen Inc., 1, 3; E. S. Siris, None; N. Binkley, Novartis, Viking, Radius, 2,Radius, Viking, 5.

To cite this abstract in AMA style:

Ferrari S, Lewiecki EM, Butler PW, Kendler DL, Napoli N, Huang S, Crittenden DB, Pannacciulli N, Siris ES, Binkley N. Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/skeletal-benefit-risk-of-long-term-denosumab-therapy-a-virtual-twin-analysis-of-fractures-prevented-to-skeletal-safety-events-observed/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/skeletal-benefit-risk-of-long-term-denosumab-therapy-a-virtual-twin-analysis-of-fractures-prevented-to-skeletal-safety-events-observed/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences